BOTANICAL AND PLANT DERIVED DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Botanical and plant derived drugs contain active ingredients derived from plants. The botanical drug is a mixture of plant materials that include whole plant, part of plants, fungi or algae. Plants have been used as a source of medicine since past, owing to side effects caused due to consumption of synthetic drugs the botanical and plant derived drugs are preferred over the synthetic drugs.

Furthermore, the botanical drugs are clinically evaluated for safety and efficacy just as conventional drugs. Besides, this legalization of medical cannabis is also expected to foster growth of the botanical and plant derived drugs market. 

Market Dynamics

The global botanical and plant derived drugs market is projected to witness significant growth over the forecast period, owing to legalization of medical cannabis. Medical cannabis was legalized in the Czech Republic, in 2013, Argentina and Chile in 2015, and in 2016, marijuana legalization in America reached a tipping point, as the medical marijuana became legal in some of the states.

Hence, many manufacturers are focused on research and development on medical cannabis to launch new drugs. For instance, one of the drug by GW Pharmaceuticals, Epidiolex consists of cannabidivarin (CBDV) is in developmental process, which will be used in clinical trials for treatment resistant epilepsy, supported by NSW and Queensland government in 2016.

Furthermore, increasing number of chronic disease supports the growth of botanical and plant derived drugs, as lung cancer accounts for the leading cause of death in the Eastern, Southern and Southeastern Asia. The region holds for 56% of the world’s population and contributes to 44% of the total cancer cases worldwide according to the statistics mentioned in the Cancer Atlas.

Key features of the study

• This report provides in-depth analysis of the Botanical and plant derived drugs market size (US$ Million) and Cumulative Annual Growth Rate (CAGR) (%) for the forecast period: 2026 – 2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global botanical and plant derived drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key companies covered as a part of this study include Bayer Healthcare, GlaxoSmithKline, Pfizer, Inc. Sanofi, Actelion Pharmaceuticals, Aimil Pharmaceuticals, Allergan, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Concordia Pharmaceuticals, GW Pharmaceuticals, LEO Pharma, MEDICAGO, and Merck.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, market expansion, and marketing tactics.
• The global botanical and plant derived drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for botanical and plant derived drugs market, research and consulting firms, new entrants, and financial analysts.

Market Segmentation (Version-2026)

• By Source (Revenue, USD Bn, 2021-2033)
  • Plant
  • Algae
  • Macroscopic fungi
  • Others
• By Dosage Form (Revenue, USD Bn, 2021-2033)
  • Pills
  • Tablets
  • Capsules
  • Injection
• By Therapeutic Application (Revenue, USD Bn, 2021-2033)
  • Central Nervous System
  • Cardiovascular Diseases
  • Infectious Diseases
  • Respiratory Diseases
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • North Africa
    • South Africa
    • Central Africa
• Key Players
  • Bayer Healthcare
  • GlaxoSmithKline
  • Pfizer, Inc.
  • Sanofi
  • Actelion Pharmaceuticals
  • Aimil Pharmaceuticals
  • Allergan
  • AstraZeneca
  • Boehringer Ingelheim
  • GW Pharmaceuticals